|Articles|January 18, 2002
Voluntary Recall of Antihemophilic Factor (Recombinant), Helixate FS / Kogenate FS
Author(s)BioPharm International Editors
Potency testing following nine weeks storage at room temperature found that the lots fell below the minimum potency specification.
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How FDA’s Bayesian Guidance Could Accelerate Adaptive Trial Design in Biopharmaceuticals
2
Beyond Transactional: Collaborative Partnerships for Rapid, Flexible Biologics Development
3
Generative AI and Adaptive Trials Shape Future Biotech Development
4
Novartis Calls for Global Governments to Address Global Trade Policy
5